Functional roles for C5a receptors in sepsis

Nature Medicine

Volumn 14, Issue 5, 2008, Pages 551-557

  Rittirsch, Daniel ^a   Flierl, Michael A ^a   Nadeau, Brian A ^a   Day, Danielle E ^a   Huber Lang, Markus ^b   Mackay, Charles R ^c   Zetoune, Firas S ^a   Gerard, Norma P ^d,e   Cianflone, Katherine ^f   Köhl, Jörg ^g,h   Gerard, Craig ^d   Sarma, J Vidya ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f LAVAL UNIVERSITY   (Canada)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C512 PROTEIN; COMPLEMENT COMPONENT C5A RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; KNOCKOUT MOUSE; LETHALITY; LIGATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SEPSIS; SURVIVAL; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CHEMOKINES; COMPLEMENT C3; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HMGB1 PROTEIN; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, CHEMOKINE; SEPSIS; SURVIVAL ANALYSIS;

MUS;

EID: 43249098418     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1753     Document Type: Article

References (38)

1. Czermak, B.J. et al. Protective effects of C5a blockade in sepsis. Nat. Med. 5, 788-792 (1999).
2. Gerard, N.P. & Gerard, C. The chemotactic receptor for human C5a anaphylatoxin. Nature 349, 614-617 (1991).
3. Gerard, C. & Gerard, N.P. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12, 775-808 (1994).
4. 74. J. Biol. Chem. 277, 7165-7169 (2002).
5. Johswich, K. et al. Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. J. Biol. Chem. 281, 39088-39095 (2006).
6. Okinaga, S. et al. C5L2, a nonsignaling C5A binding protein. Biochemistry 42, 9406-9415 (2003).
7. Kalant, D. et al. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J. Biol. Chem. 278, 11123-11129 (2003).
8. Kalant, D. et al. C5L2 is a functional receptor for acylation-stimulating protein. J. Biol. Chem. 280, 23936-23944 (2005).
9. Kildsgaard, J. et al. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165, 5406-5409 (2000).
10. Takabayashi, T. et al. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J. Immunol. 156, 3455-3460 (1996).
11. Gerard, N.P. et al. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 280, 39677-39680 (2005).
12. Johswich, K. & Klos, A. C5L2 - an anti-inflammatory molecule or a receptor for acylation stimulating protein (C3a-desArg)? Adv. Exp. Med. Biol. 598, 159-180 (2007).
13. Chen, N.J. et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446, 203-207 (2007).
14. Ohno, M. et al. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol. Immunol. 37, 407-412 (2000).
15. Huber-Lang, M. et al. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J. Immunol. 174, 1104-1110 (2005).
16. Hopken, U.E., Lu, B., Gerard, N.P. & Gerard, C. Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J. Exp. Med. 186, 749-756 (1997).
17. Otto, M. et al. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J. Biol. Chem. 279, 142-151 (2004).
18. Gao, H. et al. Evidence for a functional role of the second C5a receptor C5L2. FASEB J. 19, 1003-1005 (2005).
19. Lee, H. et al. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat. Biotechnol. 24, 1279-1284 (2006).
20. Czermak, B.J. et al. In vitro and in vivo dependency of chemokine generation on C5a and TNF-α. J. Immunol. 162, 2321-2325 (1999).
21. Gavrilyuk, V. et al. Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J. Neurochem. 92, 1140-1149 (2005).
22. Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999).
23. Muller, S. et al. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20, 4337-4340 (2001).
24. Lotze, M.T. & Tracey, K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342 (2005).
25. Suda, K. et al. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J. Surg. 30, 1755-1762 (2006).
26. Yang, H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101, 296-301 (2004).
27. Qin, S. et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203, 1637-1642 (2006).
28. Hawlisch, H. et al. C5a negatively regulates Toll-like receptor 4-induced immune responses. Immunity 22, 415-426 (2005).
29. Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110, 228-236 (2007).
30. Koleva, M. et al. Induction of anaphylatoxin C5a receptors in rat hepatocytes by lipopolysaccharide in vivo: mediation by interleukin-6 from Kupffer cells. Gastroenterology 122, 697-708 (2002).
31. Kohl, J. The role of complement in danger sensing and transmission. Immunol. Res. 34, 157-176 (2006).
32. Hawlisch, H. & Kohl, J. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol. Immunol. 43, 13-21 (2006).
33. Kim, J.Y. et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am. J. Physiol. Lung Cell. Mol. Physiol. 288, L958-L965 (2005).
34. Wang, H. et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10, 1216-1221 (2004).
35. Bonaldi, T. et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551-5560 (2003).
36. Godau, J. et al. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 173, 3437-3445 (2004).
37. Baelder, R. et al. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J. Immunol. 174, 783-789 (2005).
38. Yamada, S., Inoue, K., Yakabe, K., Imaizumi, H. & Maruyama, I. High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin. Chem. 49, 1535-1537 (2003).